Glaukos shares jumped 30% to $236.64 Thursday, on track for a record close, after the company posted third-quarter sales of $211 million, up 58% year over year, and raised its 2026 net sales guidance to $775 million to $785 million. Management also introduced preliminary 2027 guidance of $1 billion in net sales. The U.S. Glaucoma segment grew 47% to $118.6 million. Several firms raised price targets above $200.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
